Has Novavax Successfully Pivoted Its Business Model

Novavax achieved Q4 profitability by shifting to a royalty-driven model, with 73% of revenue from licensing and royalties. FY26 revenue guidance is set at $230M–$270M, excluding potential Sanofi miles...

Apellis Pharmaceuticals' stock traded near $28 last summer after the company secured FDA approval for EMPAVELI for both C3 glomerulopathy and IC-MPGN indications.

Altria Group (MO) is pivoting strategy away from declining cigarette volumes by prioritizing oral nicotine, e-vapor, and heated tobacco products to stabilize future growth trajectories.